- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00965627
Biology of Thymic Tumors
August 27, 2009 updated by: Istituto Clinico Humanitas
Biological Analysis of a Series of Thymoma and Thymic Carcinoma: Genetic Aberrations and Potential Therapy Targets.
This is a retrospective analysis of biological characteristics of thymoma and thymic carcinoma patients.
Study Overview
Status
Completed
Conditions
Detailed Description
The aim of the present study is to investigated the genetic alterations in tumor samples of a series of all WHO-defined subtypes of thymoma patients using high resolution microarray- comparative genomic hybridization (CGH) followed by hierarchical cluster analyses of the data to identify specific patterns of genetic aberrations and genes associated with each subtype.
Moreover, tumor samples will be also investigated for some specific potential therapy targets by immunoistichemistry, mutation analysis, and fluorescence in situ hybridization (FISH) analysis.
All these biological data will be correlated with clinical patients characteristics and survival data.
Study Type
Observational
Enrollment (Actual)
134
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Istituto Clinico Humanitas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Thymoma and thymic carcinoma patients will be retrospectively analyzed.
Patients will be selected based on the availability of tumor tissue.
Description
Inclusion Criteria:
- Availability of tumor tissue and patients with thymoma and thymic carcinoma
Exclusion Criteria:
- NON Availability of tumor tissue and patients with thymoma and thymic carcinoma
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Primary objective: to evaluate the presence of genetic alterations and specific potential therapy targets.
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Secondary objective: to correlate the biological characteristics with clinical characteristics and survival data of patients.
Time Frame: one year
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
August 1, 2008
Study Completion (Actual)
August 1, 2009
Study Registration Dates
First Submitted
August 6, 2009
First Submitted That Met QC Criteria
August 24, 2009
First Posted (Estimate)
August 25, 2009
Study Record Updates
Last Update Posted (Estimate)
August 28, 2009
Last Update Submitted That Met QC Criteria
August 27, 2009
Last Verified
August 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONC/OSS-01/2008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
-
Shanghai Zhongshan HospitalHuashan Hospital; West China Hospital; Tang-Du Hospital; Second Affiliated Hospital... and other collaboratorsNot yet recruitingMyasthenia Gravis Associated With Thymoma | Efgartigimod | Intravenous ImmunoglobulinChina
-
Prof. Dr. Berthold SchalkeCrolll GmbhCompletedPrimary Inoperable Thymoma | Local Recurrent ThymomaGermany
-
Tiziana Life Sciences LTDTerminatedMalignant ThymomaUnited States, Italy
-
Yale UniversityWithdrawn
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Beijing BiotechRecruitingThymic Carcinoma | B2 ThymomaChina
-
Peng LiuNot yet recruitingHistological or Cytological Confirmed Stage Ⅲ and Ⅳa ThymomaChina
-
Armando Santoro, MDCompletedThymoma and Thymic CarcinomaItaly